AIM: To study the association of the frequency and pattern of KIT and PDGFRA mutations and clinicopathological factors in a group of patients with gastrointestinal stromal tumors (GIST). METHODS: Thirty patients with GIST were examined. Exons 9, 11, 13, and 17 of the KIT and exons 12 and 18 of the PDGFRA gene were analyzed for the presence of mutations by PCR amplification and direct sequencing. RESULTS: KIT or PDGFRA mutations were detected in 21 of the 30 patients (70%). Sixteen patients had mutations within KIT exon 11, three within KIT exon 9, and two within PDGFRA exon 18. GISTs with KIT exon 9 mutations were predominantly located in the small intestine, showed a spindle cell phenotype, and were assessed as potentially malignant. GISTs with KIT exon 11 mutations were located in the stomach and intestine, showed mainly a spindle cell phenotype, and were scored as potentially malignant (P < 0.05). Tumors with KIT exon 11 codon 557/558 deletion/insertion mutations were found to be associated with a potentially malignant clinical behaviour (P < 0.003). GISTs with PDGFRA mutations located in stomach showed a mixed cell phenotype and were classified as of very low or low moderate malignant potential. CONCLUSION: Determination of KIT and PDGFRA mutations should be additional parameters for the better prediction of GISTs clinical behaviour. Tumors with deletion/insertion mutations affecting codons 557/558 of the KIT gene seem to represent a distinct subset of malignant GISTs.
AIM: To study the association of the frequency and pattern of KIT and PDGFRA mutations and clinicopathological factors in a group of patients with gastrointestinal stromal tumors (GIST). METHODS: Thirty patients with GIST were examined. Exons 9, 11, 13, and 17 of the KIT and exons 12 and 18 of the PDGFRA gene were analyzed for the presence of mutations by PCR amplification and direct sequencing. RESULTS:KIT or PDGFRA mutations were detected in 21 of the 30 patients (70%). Sixteen patients had mutations within KIT exon 11, three within KIT exon 9, and two within PDGFRA exon 18. GISTs with KIT exon 9 mutations were predominantly located in the small intestine, showed a spindle cell phenotype, and were assessed as potentially malignant. GISTs with KIT exon 11 mutations were located in the stomach and intestine, showed mainly a spindle cell phenotype, and were scored as potentially malignant (P < 0.05). Tumors with KIT exon 11 codon 557/558 deletion/insertion mutations were found to be associated with a potentially malignant clinical behaviour (P < 0.003). GISTs with PDGFRA mutations located in stomach showed a mixed cell phenotype and were classified as of very low or low moderate malignant potential. CONCLUSION: Determination of KIT and PDGFRA mutations should be additional parameters for the better prediction of GISTs clinical behaviour. Tumors with deletion/insertion mutations affecting codons 557/558 of the KIT gene seem to represent a distinct subset of malignant GISTs.
Authors: J Lasota; A Wozniak; M Sarlomo-Rikala; J Rys; R Kordek; A Nassar; L H Sobin; M Miettinen Journal: Am J Pathol Date: 2000-10 Impact factor: 4.307
Authors: N Koon; R Schneider-Stock; M Sarlomo-Rikala; J Lasota; M Smolkin; G Petroni; A Zaika; C Boltze; F Meyer; L Andersson; S Knuutila; M Miettinen; W El-Rifai Journal: Gut Date: 2004-02 Impact factor: 23.059
Authors: Cristina R Antonescu; Gunhild Sommer; Lisa Sarran; Sylvia J Tschernyavsky; Elyn Riedel; James M Woodruff; Mark Robson; Robert Maki; Murray F Brennan; Marc Ladanyi; Ronald P DeMatteo; Peter Besmer Journal: Clin Cancer Res Date: 2003-08-15 Impact factor: 12.531
Authors: K Kontogianni; M Demonakou; N Kavantzas; A Ch Lazaris; K Lariou; C Vourlakou; P Davaris Journal: Eur J Surg Oncol Date: 2003-08 Impact factor: 4.424
Authors: Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss Journal: Hum Pathol Date: 2002-05 Impact factor: 3.466
Authors: Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher Journal: Science Date: 2003-01-09 Impact factor: 47.728
Authors: P Origone; S Gargiulo; L Mastracci; A Ballestrero; L Battistuzzi; C Casella; D Comandini; R Cusano; A P Dei Tos; R Fiocca; A Garuti; P Ghiorzo; C Martinuzzi; L Toffolatti; G Bianchi Scarrà Journal: Gastric Cancer Date: 2013-01-05 Impact factor: 7.370
Authors: Jason S Gold; Mithat Gönen; Antonio Gutiérrez; Javier Martín Broto; Xavier García-del-Muro; Thomas C Smyrk; Robert G Maki; Samuel Singer; Murray F Brennan; Cristina R Antonescu; John H Donohue; Ronald P DeMatteo Journal: Lancet Oncol Date: 2009-09-28 Impact factor: 41.316
Authors: Alexander W Beham; Inga-Marie Schaefer; Philipp Schüler; Silke Cameron; B Michael Ghadimi Journal: Int J Colorectal Dis Date: 2011-11-29 Impact factor: 2.571
Authors: Angela Michelucci; Caterina Chiappetta; Jessica Cacciotti; Norman Veccia; Elisa Astri; Martina Leopizzi; Romana Prosperi Porta; Vincenzo Petrozza; Carlo Della Rocca; Generoso Bevilacqua; Andrea Cavazzana; Claudio Di Cristofano Journal: Gut Liver Date: 2012-12-05 Impact factor: 4.519